Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019

被引:691
|
作者
Pimentel-Nunes, Pedro [1 ,2 ,3 ]
Libanio, Diogo [1 ,2 ]
Marcos-Pinto, Ricardo [2 ,4 ]
Areia, Miguel [2 ,5 ]
Leja, Marcis [6 ]
Esposito, Gianluca [7 ]
Garrido, Monica [4 ]
Kikuste, Ilze [6 ]
Megraud, Francis [8 ,9 ]
Matysiak-Budnik, Tamara [10 ]
Annibale, Bruno [7 ]
Dumonceau, Jean-Marc [11 ]
Barros, Rita [12 ,13 ]
Flejou, Jean-Francois [14 ]
Carneiro, Fatima [12 ,13 ,15 ,16 ]
van Hooft, Jeanin E. [17 ]
Kuipers, Ernst J. [18 ]
Dinis-Ribeiro, Mario [1 ,2 ]
机构
[1] Portuguese Oncol Inst Porto, Dept Gastroenterol, Rua Dr Bernardino de Almeida, P-4200072 Porto, Portugal
[2] Ctr Res Hlth Technol & Informat Syst CINTESIS, Fac Med, Porto, Portugal
[3] Univ Porto, Fac Med, Surg & Physiol Dept, Porto, Portugal
[4] Univ Porto ICBAS UP, Inst Biomed Sci, Dept Gastroenterol, Porto Univ Hosp Ctr, Porto, Portugal
[5] Portuguese Oncol Inst Coimbra, Dept Gastroenterol, Coimbra, Portugal
[6] Univ Latvia, Inst Clin & Prevent Med, Ctr Digest Dis, GASTRO, Riga, Latvia
[7] Univ Sapienza Roma, Dept Med Surg & Translat Med, Univ Hosp St Andrea, Rome, Italy
[8] Univ Bordeaux, INSERM, U1053, Bordeaux, France
[9] CHU Pellegrin, Lab Bacteriol, Bordeaux, France
[10] Univ Nantes, CHU Nantes, IMAD, Hepatogastroenterol & Digest Oncol, Nantes, France
[11] Gedyt Endoscopy Ctr, Buenos Aires, DF, Argentina
[12] Univ Porto Ipatimup, Inst Mol Pathol & Immunol, Porto, Portugal
[13] Univ Porto, Inst Invest & Inovacao Saude I3S, Porto, Portugal
[14] Sorbonne Univ, Hop St Antoine, AP HP, Serv Anat Pathol,Fac Med, Paris, France
[15] Ctr Hosp Sao Joao, Dept Pathol, Porto, Portugal
[16] Fac Med, Porto, Portugal
[17] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands
[18] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
关键词
GASTRIC-CANCER RISK; CHRONIC ATROPHIC GASTRITIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTERLEUKIN-1 GENE POLYMORPHISMS; WHITE-LIGHT ENDOSCOPY; COST-UTILITY ANALYSIS; PROSPECTIVE FOLLOW-UP; INTESTINAL METAPLASIA; PYLORI ERADICATION; PERNICIOUS-ANEMIA;
D O I
10.1055/a-0859-1883
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Main Recommendations Patients with chronic atrophic gastritis or intestinal metaplasia (IM) are at risk for gastric adenocarcinoma. This underscores the importance of diagnosis and risk stratification for these patients. High definition endoscopy with chromoendoscopy (CE) is better than high definition white-light endoscopy alone for this purpose. Virtual CE can guide biopsies for staging atrophic and metaplastic changes and can target neoplastic lesions. Biopsies should be taken from at least two topographic sites (antrum and corpus) and labelled in two separate vials. For patients with mild to moderate atrophy restricted to the antrum there is no evidence to recommend surveillance. In patients with IM at a single location but with a family history of gastric cancer, incomplete IM, or persistent Helicobacter pylori gastritis, endoscopic surveillance with CE and guided biopsies may be considered in 3 years. Patients with advanced stages of atrophic gastritis should be followed up with a high quality endoscopy every 3 years. In patients with dysplasia, in the absence of an endoscopically defined lesion, immediate high quality endoscopic reassessment with CE is recommended. Patients with an endoscopically visible lesion harboring low or high grade dysplasia or carcinoma should undergo staging and treatment. H. pylori eradication heals nonatrophic chronic gastritis, may lead to regression of atrophic gastritis, and reduces the risk of gastric cancer in patients with these conditions, and it is recommended. H. pylori eradication is also recommended for patients with neoplasia after endoscopic therapy. In intermediate to high risk regions, identification and surveillance of patients with precancerous gastric conditions is cost-effective.
引用
收藏
页码:365 / 388
页数:24
相关论文
共 4 条
  • [1] Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)
    Dinis-Ribeiro, M.
    Areia, M.
    de Vries, A. C.
    Marcos-Pinto, R.
    Monteiro-Soares, M.
    O'Connor, A.
    Pereira, C.
    Pimentel-Nunes, P.
    Correia, R.
    Ensari, A.
    Dumonceau, J. M.
    Machado, J. C.
    Macedo, G.
    Malfertheiner, P.
    Matysiak-Budnik, T.
    Megraud, F.
    Miki, K.
    O'Morain, C.
    Peek, R. M.
    Ponchon, T.
    Ristimaki, A.
    Rembacken, B.
    Carneiro, F.
    Kuipers, E. J.
    VIRCHOWS ARCHIV, 2012, 460 (01) : 19 - 46
  • [2] Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)
    Dinis-Ribeiro, M.
    Areia, M.
    de Vries, A. C.
    Marcos-Pinto, R.
    Monteiro-Soares, M.
    O'Connor, A.
    Pereira, C.
    Pimentel-Nunes, P.
    Correia, R.
    Ensari, A.
    Dumonceau, J. M.
    Machado, J. C.
    Macedo, G.
    Malfertheiner, P.
    Matysiak-Budnik, T.
    Megraud, F.
    Miki, K.
    O'Morain, C.
    Peek, R. M.
    Ponchon, T.
    Ristimaki, A.
    Rembacken, B.
    Carneiro, F.
    Kuipers, E. J.
    ENDOSCOPY, 2012, 44 (01) : 74 - 94
  • [3] Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)
    M. Dinis-Ribeiro
    M. Areia
    A. C. de Vries
    R. Marcos-Pinto
    M. Monteiro-Soares
    A. O’Connor
    C. Pereira
    P. Pimentel-Nunes
    R. Correia
    A. Ensari
    J. M. Dumonceau
    J. C. Machado
    G. Macedo
    P. Malfertheiner
    T. Matysiak-Budnik
    F. Megraud
    K. Miki
    C. O’Morain
    R. M. Peek
    T. Ponchon
    A. Ristimaki
    B. Rembacken
    F. Carneiro
    E. J. Kuipers
    Virchows Archiv, 2012, 460 : 19 - 46
  • [4] Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025
    Dinis-Ribeiro, Mario
    Libanio, Diogo
    Uchima, Hugo
    Spaander, Manon C. W.
    Bornschein, Jan
    Matysiak-Budnik, Tamara
    Tziatzios, Georgios
    Santos-Antunes, Joao
    Areia, Miguel
    Chapelle, Nicolas
    Esposito, Gianluca
    Fernandez-Esparrach, Gloria
    Kunovsky, Lumir
    Garrido, Monica
    Tacheci, Ilja
    Link, Alexander
    Marcos, Pedro
    Marcos-Pinto, Ricardo
    Moreira, Leticia
    Pereira, Ana Carina
    Pimentel-Nunes, Pedro
    Romanczyk, Marcin
    Fontes, Filipa
    Hassan, Cesare
    Bisschops, Raf
    Feakins, Roger
    Schulz, Christian
    Triantafyllou, Konstantinos
    Carneiro, Fatima
    Kuipers, Ernst J.
    ENDOSCOPY, 2025,